A Randomized Controlled Trial of Antidepressant Continuation for Major Depression Following Traumatic Brain Injury

Mark J. Rapoport, MD, FRCPC; Robert A. Mitchell, BSc; Scott McCullagh, MD, FRCPC; Nathan Herrmann, MD, FRCPC; Florance Chan, MSc; Alex Kiss, PhD; Anthony Feinstein, MD, FRCPC; and Krista L.Lanctôt, PhD

Published: April 20, 2010

Article Abstract

Objective: This study examines whether continuation therapy with citalopram can prevent a relapse following remission of major depression due to traumatic brain injury.

Method: After 65 subjects with DSM-IV-diagnosed major depression following traumatic brain injury were treated with open-label citalopram (20 mg to 50 mg/d), 25 subjects (38.5%) met criteria for remission. Of those, 21 (84.0%) were randomly assigned to either same-dose citalopram or placebo and followed monthly over 40 weeks. Remission was defined as a Hamilton Depression Rating Scale (HDRS) score of ≤‘ ‰7 or a Clinical Global Impressions-Improvement rating of "much improved" or better. The main outcome variable was the presence of relapse, as defined by meeting criteria for major depressive episode according to the DSM-IV and an HDRS score ≥‘ ‰16. Data were collected from February 16, 2005, to May 5, 2008.

Results: Ten subjects were randomly assigned to citalopram and 11 to placebo. There were 3 dropouts, including 1 for adverse drug effects (diarrhea). Relapse occurred in 11 subjects (52.4%), with a mean‘ ‰±‘ ‰SD time to relapse of 23.52‘ ‰±‘ ‰16.6 weeks. The groups did not differ in relapse rates (drug: 50.0% [5/10] vs placebo: 54.5% [6/11], Fisher exact test, P‘ ‰=‘ ‰.835) or time to relapse (log rank test χ2‘ ‰=‘ ‰0.148, P‘ ‰=‘ ‰.700).

Conclusions: The present study suggests important limitations of continuation pharmacotherapy in the prevention of relapse of major depression following traumatic brain injury.

Trial Registration: clinicaltrials.gov Identifier: NCT00162916

J Clin Psychiatry

Submitted: December 15, 2008; accepted April 21, 2009.

Online ahead of print: April 20, 2010 (doi:10.4088/JCP.09m05086blu).

Corresponding author: Mark J. Rapoport, MD, FRCPC, 2075 Bayview Ave, Rm FG37, Toronto, Ontario, M4N 3M5, Canada (mark.rapoport@sunnybrook.ca).

Volume: 71

Quick Links: Depression (MDD)

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF

Sign-up to stay
up-to-date today!


Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...